Leucocyte antibodies in blood donors and a look back on recipients of their blood components

Institute of Haematology and Blood Transfusion, Warsaw, Poland.
Vox Sanguinis (Impact Factor: 3.3). 05/2007; 92(3):247-9. DOI: 10.1111/j.1423-0410.2007.00890.x
Source: PubMed

ABSTRACT The role of leucocyte antibodies in donors is poorly understood in pathogenesis of transfusion-related acute lung injury (TRALI). We examined antibodies in donors and traced recipients transfused with their blood components.
Antibodies were examined in 1043 donors by five methods, look back performed in 26 recipients.
Anti-human leucocyte antigen detected by enzyme-linked immunosorbent assay in 9.8% women but none in men. Specificities identified using FlowPRA, antibodies detected after several months. TRALI reported in one recipient from immunized donor. In 11 of 26 recipients without TRALI, cognate antigens were identified.
Detection of antibodies in donors cannot predict TRALI, even in recipients with cognate antigen(s).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Blood transfusions are common during hematopoietic stem cell transplantation (HSCT) and may contribute to lung injury. This study examined the associations between red blood cell (RBC) and platelet (PLT) transfusions and idiopathic pneumonia syndrome (IPS) among 914 individuals who underwent myeloablative allogeneic HSCT between 1997 and 2001. Patients received allogeneic blood transfusions at their physicians' discretion. RBCs, PLTs, and a composite of "other" transfusions were quantified as the sum of units received each 7-day period from 6 days before transplant until IPS onset, death, or Posttransplant Day 120. RBC and PLT transfusions were modeled as separate time-varying exposures in proportional hazards models adjusted for IPS risk factors (age, baseline disease, irradiation dose) and other transfusions. Timing of PLT transfusion relative to myeloid engraftment and PLT ABO blood group (match vs. mismatch) were included as potential interaction terms. Patients received a median of 9 PLT and 10 RBC units. There were 77 IPS cases (8.4%). Each additional PLT unit transfused in the prior week was associated with 16% higher IPS risk (hazard ratio, 1.16; 95% confidence interval, 1.09-1.23; p < 0.001). Recent RBC and PLT transfusions were each significantly associated with greater risk of IPS when examined without the other; only PLT transfusions retained significance when both exposures were included in the model. The PLT association was not modified by engraftment or ABO mismatch. PLT transfusions are associated with greater risk of IPS after myeloablative HSCT. RBCs may also contribute; however, these findings need confirmation.
    Transfusion 08/2013; 54(4). DOI:10.1111/trf.12396 · 3.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Transfusion-related acute lung injury (TRALI) is the leading cause of mortality following transfusion of blood components. Characteristic for TRALI is acute hypoxemia during or up to 6 h after transfusion provided that cardiogenic respiratory failure and transfusion-associated circulatory overload (TACO) are excluded. In this article we present: 1) Etiology and pathomechanism of TRALI syndrome including the numerous issues that are still unresolved. Currently accepted is the multiple-event model which involves both the patient and the transfused blood components. The TRALI syndrome may be either immunological or nonimmunological dependant on the various factors that activate neutrophils – the main cells in TRALI pathogenesis. 2) TRALI diagnosis should be based mainly on the clinical presentation due to the variety of pathomechanism of the syndrome; however testing of anti-leukocyte antibodies in transfused blood components, according to ISBT guidelines, is recommended in order to prevent TRALI incidence. 3) Different strategies of TRALI prevention, although up to date no ultimate provisions have been accepted. Transfusion of plasma collected only from men seems to be a promising solution as in many countries that adapted this preventive measure the number of TRALI cases has substantially decreased. 4) Different methods of proceeding with donors who donated blood components that were the cause of TRALI in transfused patients. It still remains an open question whether to defer donors with anti-leukocyte antibodies or multi pregnant women.
    Acta haematologica Polonica 07/2013; 44(3):274–283. DOI:10.1016/j.achaem.2013.07.021
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibody-mediated TRALI reduction strategies include the exclusion of high plasma volume blood components from risk donors or testing of these donors for leucocyte antibodies, i.e. HLA class I, HLA class II, and HNA antibodies. Recommendations for the detection of leucocyte antibodies have been made by the ISBT Working Party on Granulocyte Immunobiology.
    ISBT Science Series 11/2009; 4(n2). DOI:10.1111/j.1751-2824.2009.01244.x


Available from
May 27, 2014